

Myelofibrosis (MF) Pipeline Analysis 2019 (H1)

<https://marketpublishers.com/r/M464B163089EEN.html>

Date: May 2019

Pages: 79

Price: US\$ 2,400.00 (Single User License)

ID: M464B163089EEN

Abstracts

Myelofibrosis Pipeline Analysis report 2019 (H1) covers more than 10 drugs currently in different phases of development. Myelofibrosis is a chronic serious disorder which disrupts the normal production of the blood cells due to the excessive scarring in the bone marrow and belongs to a group of diseases called myeloproliferative disorders. The exact cause of the disease is yet not known however, some mutations affecting proteins that work in signaling pathways in the cells may be considered as the reason. Common symptoms of myelofibrosis are splenomegaly, fatigue, paler mucous membranes, and cachexia. Diagnoses are done by blood tests, bone marrow biopsy, and imaging tests.

The report provides Myelofibrosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are AbbVie, CTI BioPharma Corp., NS Pharma, Inc, and Bristol Myers Squibb among others.

Scope:

By Company

By Phase

By Molecule Type

By Region

By Route of Administration

Contents

1. INTRODUCTION

- 1.1. Research Methodology
- 1.2. Research Scope
 - 1.2.1. Analysis by Company
 - 1.2.2. Analysis by Phase
 - 1.2.3. By Molecule Type
 - 1.2.4. By region

2. DISEASE OVERVIEW

- 2.1.1. Introduction
- 2.1.2. Classification
- 2.1.3. Symptoms
- 2.1.4. Causes
- 2.1.5. Diagnoses
- 2.1.6. Treatment
- 2.1.7. Epidemiology

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

- 4.1. Drivers
- 4.2. Restraints
- 4.3. Opportunities

5. PIPELINE ANALYSIS/OUTLOOK

- 5.1. Analysis by Company
- 5.2. Analysis by Phase
 - 5.2.1. Phase of Development
 - 5.2.1.1. Introduction
 - 5.2.1.1.1. Drug Profiling
 - Drug Name
 - Generic Name
 - Synonyms

- Company
- Collaborator
- Route of administration
- Target
- Mechanism of Action
- Technology
- Molecule type
- CAS Number
- Weight
- Chemical Formula
- IUPAC name
- ATC code
 - 5.2.1.1.2. Strategic Developments
 - 5.2.1.1.3. Clinical trials
 - 5.2.1.1.4. Clinical trial results
 - 5.2.1.1.5. Patents
 - 5.2.1.1.6. Technology
- 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
- 5.3. By Molecule type
- 5.4. Analysis by Region

6. COMPANY PROFILING

- 6.1. AbbVie
 - 6.1.1. Introduction
 - 6.1.2. Financials
 - 6.1.3. Products and Services
 - 6.1.4. SWOT
 - 6.1.5. Recent Development
- 6.2. Constellation Pharmaceuticals
 - 6.2.1. Introduction
 - 6.2.2. Financials
 - 6.2.3. Products and Services
 - 6.2.4. SWOT
 - 6.2.5. Recent Development
- 6.3. CTI BioPharma Corp.
 - 6.3.1. Introduction
 - 6.3.2. Financials
 - 6.3.3. Products and Services

- 6.3.4. SWOT
- 6.3.5. Recent Development
- 6.4. Celgene Corp
 - 6.4.1. Introduction
 - 6.4.2. Financials
 - 6.4.3. Products and Services
 - 6.4.4. SWOT
 - 6.4.5. Recent Development
- 6.5. Acceleron Pharma, Inc.
 - 6.5.1. Introduction
 - 6.5.2. Financials
 - 6.5.3. Products and Services
 - 6.5.4. SWOT
 - 6.5.5. Recent Development
- 6.6. Celgene Corp
 - 6.6.1. Introduction
 - 6.6.2. Financials
 - 6.6.3. Products and Services
 - 6.6.4. SWOT
 - 6.6.5. Recent Development
- 6.7. NS Pharma, Inc.
 - 6.7.1. Introduction
 - 6.7.2. Financials
 - 6.7.3. Products and Services
 - 6.7.4. SWOT
 - 6.7.5. Recent Development
- 6.8. Astra Zeneca
 - 6.8.1. Introduction
 - 6.8.2. Financials
 - 6.8.3. Products and Services
 - 6.8.4. SWOT
 - 6.8.5. Recent Development
- 6.9. Bristol Myers Squibb
 - 6.9.1. Introduction
 - 6.9.2. Financials
 - 6.9.3. Products and Services
 - 6.9.4. SWOT
 - 6.9.5. Recent Development
- 6.10. Stemline Therapeutics

- 6.10.1. Introduction
- 6.10.2. Financials
- 6.10.3. Products and Services
- 6.10.4. SWOT
- 6.10.5. Recent Development
- 6.11. Kartos Therapeutics
 - 6.11.1. Introduction
 - 6.11.2. Financials
 - 6.11.3. Products and Services
 - 6.11.4. SWOT
 - 6.11.5. Recent Development
- List of Tables
- List of Figures

I would like to order

Product name: Myelofibrosis (MF) Pipeline Analysis 2019 (H1)

Product link: <https://marketpublishers.com/r/M464B163089EEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M464B163089EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970